The possibility that allogeneic T cells may be targeted to leukemia has important therapeutic implications. As most tumor antigens represent self-proteins, high-avidity tumorspecific T cells are largely deleted from the repertoire of the patient. In contrast, T cells from major histocompatibility complex (MHC)-mismatched donors provide naïve repertoires wherein such cells have not been systematically eliminated. Yet, evidence for peptide degeneracy or poly-specificity warrants caution in the use of foreign human leukocyte antigen (HLA) or peptide complexes as therapeutic targets. Here, we cocultured HLA-A*0201-negative T cells with autologous dendritic cells engineered to present HLA-A*0201 complexed with a peptide from the B cell antigen CD20 (CD20p). HLA-A*0201/CD20p pentamer-reactive CD8 þ T cells were readily obtained from all donors. The polyclonal cells showed exquisite peptide and MHC specificity, and efficiently killed HLA-A*0201-positive B cells, including primary chronic lymphocytic leukemia cells. The T cell receptor (TCR) sequences displayed a novel type of conservation, with extensive homology in the TCR b chain complementarity-determining region 3 and in J, but not V, region. This is surprising, as the donors were HLA disparate and their TCR repertoires are expected to show little overlap. The results demonstrate the first public recognition motif for an allogeneic HLA/peptide complex. The allo-restricted T cells or TCRs could provide graft-versus-leukemia in the absence of graft-versus-host disease.
Introduction
Donor T cells contribute significantly to the curative effect of allogeneic hematopoietic stem cell transplantation. 1 A major limitation is that T cell specificities mediating beneficial graftversus-leukemia effects cannot be readily separated from those causing graft-versus-host disease. 2 The outcome is therefore unpredictable.
An attractive possibility is to exploit the immunogenicity of foreign human leukocyte antigen (HLA) molecules to target T cell reactivity to leukemia. 3 As tolerance is limited to self-HLA, any peptide is a potential immunogen when presented on a foreign HLA molecule. A complex of a frequent HLA molecule and a peptide from a protein with cell type-restricted expression could be a useful therapeutic target shared by many individuals. T cells capable of recognizing the complex might be used to selectively kill the cells expressing the protein, or T cell receptors (TCRs) could be cloned and transferred to patient T cells. A mismatch on one HLA allele is permitted in the setting of a standard allogeneic hematopoietic stem cell transplantation.
Although allo-recognition is peptide dependent, there is considerable controversy with regard to the specificity that can be obtained. The high frequency of allo-reactive T cells in the mature repertoire is generally interpreted as an indication of low peptide specificity. 4, 5 Extensive studies have concluded that TCRs have an inherent predisposition to react with features shared by all major histocompatibility complex (MHC) molecules, and that negative selection is essential to remove polyreactive T cells. The results suggest that most allo-reactive T cells show a high degree of peptide degeneracy. 6, 7 Other studies have reported that allo-reactive cells are poly-specific rather than peptide-degenerate. [8] [9] [10] This implies that the cells are peptide specific but capable of recognizing a larger number of different peptides than those reactive with foreign peptides on self-MHC.
If allo-reactive cells are inherently poly-specific or peptidedegenerate, foreign HLA molecules are not suitable as therapeutic targets. Further evidence in support of this view comes from a number of additional studies. [11] [12] [13] [14] It therefore seems justified to ask whether the few peptide-specific cytotoxic T cell clones (CTLs) obtained in some previous studies 5, 11, [15] [16] [17] represent rare exceptions, or if specificity may not have been adequately examined.
The aim of the present study was to obtain T cells that specifically kill B cells, and to address the question of peptide specificity on foreign HLA in detail. The data demonstrate that cells reactive with HLA-A2 in complex with a peptide from the B cell antigen CD20 (CD20p) were readily obtained from all HLA-A2 neg donors tested. HLA/peptide specificity was the rule rather than the exception. DNA sequencing of the TCR repertoires provided a likely molecular explanation for the high degree of specificity: T cells from HLA-disparate donors shared a recognition motif for HLA-A2/CD20 in the complementarity-determining region 3 (CDR3) domain of the TCR b chains. Thus, an allogeneic HLA/peptide complex can recruit a narrow range of TCRs that mediate highly specific recognition. T cells reactive with HLA-A2/CD20p, or their receptors, may be used to obtain graft-versus-leukemia in the absence of graft-versus-host disease. Table 2 , were synthesized by Proimmune Ltd (Oxford, UK), except for the MART-1 (melanoma antigen recognized by T cells) dextramer (Immudex, Dako, Glostrup, Denmark). Phycoerythrin-labeled multimers containing alanine substitutions, and the corresponding CD20p wt multimer, were produced by a UV-mediated peptide exchange, as previously described. 18 Monocyte-derived dendritic cells and T cell lines were generated as described in Stronen et al. 19 and in Supplementary Information Methods. T cell clones were obtained by limiting dilution.
Materials and methods

Donors
mRNA and DNA transfection, plasmid construction and analysis of TCR sequences HLA-A*0201 mRNA generated as previously described 19 was transfected by electroporation (1250 V/cm) into monocytederived dendritic cells, and the HaCaT keratinocyte cell line (3 ms) and EBV-transformed lymphoblastoid cell line (1 ms) with a BTX ECM 830 square wave electroporator. Human embryonic kidney (HEK) 293 cells were transfected with DNA using FuGENE-6 (Roche, Basel, Switzerland) following the manufacturer's protocol.
CD20 and MART-1 were amplified with Pfx (Invitrogen, CA, USA), as described in Supplementary Information Methods. TCR cloning was performed as described in Rosenberg et al. 20 and Supplementary Information Methods.
Flow cytometry
Cells were labeled with multimers and antibodies, and functional T cell responses were measured as described in Stronen et al. 19 and in Supplementary Information Methods, and analyzed on fluorescence-activated cell sorting (FACS) Calibur and FACS Canto II flow cytometers (BD Biosciences, CA, USA). Data analysis was performed using CellQuest Pro, FACS DiVa (BD Biosciences) and FlowJo (Tree Star Inc., Ashland, OR, USA) softwares.
Results
T cells reactive with A2/CD20 are readily obtained from HLA-A2 neg donors
To optimize T cell priming and limit irrelevant allo-reactivity, T cells from HLA-A*0201 neg donors were cocultured with autologous monocyte-derived dendritic cells that were transfected with HLA-A*0201 by a method previously developed in our laboratory 19 and pulsed with the CD20 188À196 (SLFLGILSV) peptide. 21 HLA-A*0201/CD20p (A2/CD20) pentamer-reactive cells were found on day 12 of culture for 5/6 donors at a median frequency of 0.22% of CD8 þ T cells, and on day 19 of culture for 6/6 donors at a median frequency of 0.57% of CD8 þ T cells (range 0.12-2.79%) (Figure 1a ). The frequencies of cells binding the A2/CD20 pentamers were negligible before coculture (Figure 1b) .
The CD20p used in this study was previously reported to be immunogenic in an autologous setting. 21 Peptide-pulsed monocyte-derived dendritic cells from two HLA-A*0201 pos donors were thus cocultured with autologous T cells. However, the frequencies of pentamer-reactive cells were similar to those staining with a control pentamer even after weekly restimulation for 4-5 weeks (Figure 1c) . These results are consistent with the view that HLA-A2 pos individuals are largely tolerant to this self-antigen. Sorted CD8 þ T cells reactive with the A2/CD20 pentamer remained pentamer-reactive during 2-6 weeks of antigenindependent expansion, and showed an early effector memory immunophenotype (Supplementary Figure 1) .
HLA typing showed that no HLA allele was shared by all four donors (Supplementary Table 1 ). Thus, it is highly unlikely that expansion of the CD20-specific T cells is driven by a pathogen presented by a common self-HLA-antigen, resulting in CTLs fortuitously cross-reacting with allogeneic A2/CD20.
A2/CD20-reactive T cells specifically recognize the CD20 188À196 peptide
In view of previous studies showing that allo-reactive T cell lines frequently show a high degree of peptide promiscuity, it was of interest to determine whether the A2/CD20-reactive cell lines were capable of binding HLA-A*0201 in complex with peptides other than the CD20p. The copy number of each peptide presented on cells is low. Therefore, we first tested a total of 42 pentamers, each displaying one irrelevant peptide with a varying homology to the CD20p (Supplementary Table 2 ). All peptides were biochemically confirmed to bind to HLA-A*0201 with high affinity. As expected, the A2/CD20-specific cell lines were brightly positive for the A2/CD20 pentamer (Supplementary Table 2 ). An HLA-A*0201-restricted, CMV pp65 495À503 pentamer-reactive cell line expanded from an HLA-A*0201 pos donor was included as a control. All the three cell lines stained negatively for irrelevant pentamers. Collectively, these results suggested that peptide recognition was specific.
A2/CD20-specific TCRs depend on 6-9 amino-acid residues for recognition of the CD20p
Amino-acid substitution studies may be used to assess the fine specificity of T cells. Dependence on many amino acids for recognition indicates a high degree of specificity. We prepared HLA-A*0201 multimers containing peptides in which each of the amino acids in the CD20p was singly replaced with an alanine residue. The results in Figure 2a show the binding of pentamers containing substituted peptides to an A2/CD20-specific T cell line. Four of the central amino acids (P4-7) were most critical, but no single amino-acid substitution resulted in loss of binding to all the cells in the line. This suggested that the CD20-specific T cell lines were composed either of multiple peptide-specific subsets that each required slightly different CD20 amino-acid residues, or of a mixture of clones with variable degree of specificity. To address this issue in more detail, individual clones were examined. Figure 2b shows the binding of the pentamers containing substituted peptides to a T cell clone compared with binding of pentamers presenting the wt peptide. Substitutions in positions 1, 4, 5, 6, 7 and 8 led to a reduction in binding. Of a total of four clones, all shared strong dependency on the four central amino acids in the peptide, but showed variable dependency on the remaining amino acids (Figure 2c ). Overall, the clones depended on 6-9 amino acids for recognition. Interestingly, substitution in position 9 led to enhanced binding to all but one clone. Thus, a high degree of specificity in the interaction with the CD20p epitope appeared to be a common characteristic.
A2/CD20-reactive T cells respond selectively to cells co-expressing CD20 and HLA-A*0201
Testing of reactivity against cells is a stringent measure of specificity, as any cell type is likely to present hundreds of peptides on a given HLA molecule. When pentamer-reactive T cell lines were stimulated by HLA-A*0201 pos EBV-transformed lymphoblastoid cell lines expressing CD20, approximately half of the population in all T cell lines released cytotoxic granules and produced interferon-g (Figure 3a ). The responses were reduced but not completely inhibited by antibodies against HLA class I. This might in part reflect insufficient concentrations of the antibody. Autologous (HLA-A*0201 neg ) EBV-transformed lymphoblastoid cell lines became stimulatory only after transfection with the HLA-A*0201 alloantigen. The HLA-A*0201 pos CD20 pos B-prolymphocytic leukemia cell line JVM-2 was also efficiently recognized ( Figure 3a ). CD4 þ T cells share many antigens with B cells and are highly susceptible to lysis by CD8 cells. 22 This population is therefore a useful specificity control and induced minimal activation of the A2/CD20-reactive T cells, unless loaded with the CD20p (Figure 3b) .
We next demonstrated that the pentamer-reactive cell lines mounted a vigorous response to the HEK cell line HEK 293 only after cotransfection with CD20 and HLA-A*0201, but not following transfection with MART-1 and HLA-A*0201, or with CD20 or HLA-A*0201 alone (Figure 3c ). These results strongly indicate that the CTLs recognize naturally processed and presented SLFLGILSV peptide from CD20, although formal proof awaits direct identification of the peptide by mass spectrometry.
The results in Figure 2 clearly demonstrated that the cells were polyclonal. Even so, it was conceivable that only a few clones contributed to the responses. Seven T cell clones expressing distinct Vb chains derived from the two donors were stimulated by HLA-A*0201 pos primary monocytes, primary mesenchymal stem cells, keratinocytes (HaCaT) or primary CD4 þ T cells. Minimal T cell responses were observed, whereas all cell types induced vigorous responses of similar magnitude inter-clonally when loaded with the CD20p (Figure 3d) .
The target cells used in Figures 3b-d were unmatched except for HLA-A*0201. Thus, the experiments also demonstrated lack of cross-reactivity of the CD20-specific CTLs with other HLA molecules. Altogether, the data indicated that the CTLs were highly peptide-and MHC-specific, and that the responses in the polyclonal cell lines were exerted by a high number of clones.
A2/CD20-specific T cells efficiently kill chronic lymphocytic leukemia (CLL) cells
To investigate the potential utility of the CD20-specific CTLs in immunotherapy of leukemia, we tested their ability to kill cells from the peripheral blood of CLL patients. Figure 4 shows that HLA-A*0201 pos cells were efficiently lysed at an effector/ target (E/T) ratio of only 1:1, whereas HLA-A*0201 neg CLL cells were spared, in spite of being unmatched on HLA. Supplementing the cultures with CTL lines enhanced the viability of HLA-A*0201 neg CLL cells, probably due to secreted and membrane-bound factors on the T cells.
A2/CD20-specific TCRs show a high degree of homology in the CDR3 and junctional (J) regions
To determine whether the HLA-A*0201/CD20p complex selected a restricted set of TCR domains, we sequenced the TCRs from 11 A2/CD20 pentamer þ T cell clones from three donors, and 13 additional b and a chains from the CTL lines of donor 3 and 4 ( Figure 5) . Surprisingly, there was a striking conservation of the b-chain CDR3. A large majority (19/24, 79%) shared the same, relatively short, length of 13 amino acids (start: CASS, stop: EQYF). J2-7 was found in 71%, whereas another J2 subtype was demonstrated in 5/7 of the remaining b-chains. All but four (83%) of the CDR3 b-chains had glycine in position 6. The G was often followed by a hydrophobic amino acid, notably V, L or I in position 7, and in the large majority, position 8 was occupied by a small amino acid (A, T, S or G). Strikingly, no conservation was found in the Vb segment usage, in contrast to the type I-III TCR bias described previously for antigen-specific T cell repertoires restricted by self-MHC. 23 Finally, no conservation was found in the TCRa chains.
TCR sequences with few minimal random nucleotide additions may have low peptide specificity. 24 As shown in Supplementary Table 4, the sequenced CDR3b chains were far from near germ line, containing an average of 4.8 nucleotide additions. 
Discussion
The present study demonstrates that allo-reactivity can be selectively targeted to an antigen found on B cells only. The CTLs that were obtained showed high functional avidity as they efficiently killed leukemic B cells from HLA-A2 pos donors while sparing non-B cells. Although several previous studies report on the generation of allo-restricted CTLs, peptide specificity on foreign MHC remains controversial. Specificity is fundamental for successful therapy. Our study was therefore designed to address this question in greater detail than previously done. Exquisite peptide and HLA specificity was demonstrated when CTL lines and clones obtained from four HLA-disparate donors were examined by a large number of analyses at the single-cell level. As the responses were polyclonal, these results are representative for a large number of T cell clones, in contrast to previous studies. Finally, we show for the first time that an allo-antigen can select a common antigen-binding motif in the TCR repertoires of HLA-disparate donors, suggesting a molecular explanation for the high degree of specificity observed. Thus, our extensive analysis seems to contradict the view that allo-reactive cells have poor peptide specificity.
Peptide specificity has previously been demonstrated, but mostly for one or a few allo-reactive clones. 5, 11, [15] [16] [17] Thus, the majority of studies have suggested that most allo-reactive T cells show a high degree of peptide degeneracy 6, 7 or polyspecificity. [8] [9] [10] Other reports have shown that allo-reactive cell lines or clones generated against CD45, MART-1 or MDM-2 cross-react extensively with cells that are negative for the target proteins, [11] [12] [13] or even HLA-A2. 12, 14 A cell line reactive with FMLN-1 was found to consist of a single clone, 17 and this clone was later shown to be cross-reactive. This warrants caution in the interpretation of data on specificity achieved with lines in which the number of clones has not been determined, 25 or when cross-reactivity has been tested against a limited number of peptides. 26 In the current study, the responses were highly polyclonal. Yet, a high degree of peptide specificity was indicated by the following results: Pan-A2-reactive cells were not observed when testing reactivity with HLA-A2 pentamers complexed with 42 irrelevant peptides; the CTLs were dependent on as many as 6-9 amino acids for recognition of the peptide; and negligible responses were obtained when stimulating with HLA-A2 pos T cells, monocytes, mesenchymal stem cells, keratinocytes and HEK293. As these target cells shared HLA-A2, but were otherwise unmatched, these experiments would also have revealed potential cross-reactivity with other HLA alleles, as would the control HLA-A2 neg target CLL cells. Thus, the CTLs were capable of specifically recognizing HLA-A2/CD20 amidst a plethora of HLA/peptide complexes. Collectively, these results provide strong evidence that peptide and HLA specificity was the rule rather than the exception.
The most interesting result is perhaps that the HLA-A2/CD20p complex was recognized by a conserved CDR3 motif in the b chains. To the best of our knowledge, homology in the antigenbinding regions of TCRs has not previously been reported across MHC background and represents a hitherto unrecognized form of TCR conservation. The strongly biased TCR b chains were specifically selected during our allo-stimulatory protocol. Thus, J2-7 was more than sevenfold enriched as compared with the frequency reported for the pooled T cells of 550 healthy donors. 27 Moreover, although the CDR3 length is reported to follow a bell-shaped curve that peaks at 15 amino acids, 27 we observed a length of 13 amino acids in the large majority of the b chain CDR3, as opposed to a variety of lengths seen for the CDR3 of the a chains. Although there is a weak bias for a glycine residue in position 6 in an 'ideal' TCRb of 15 amino acids, 27 we observed this residue in almost all of our TCRs.
Another interesting result was that the TCR homology found for allo-restricted T cells was different from that observed in autologous responses to viral antigens (reviewed in Turner et al.
23
) or to tumor-associated antigens in melanoma patients. 28 These responses are all restricted by an HLA antigen shared by the individuals. Three subtypes have been defined according to the type and degree of homology, but common for all is that the V regions of the a or b chains are shared. 23, 28 In the CD20-specific TCRs found here, conservation was restricted to the J region and the CDR3b.
The phenomenon of public TCRs is not completely understood, as there is little overlap in the TCR repertoires between individuals. The simplest explanation for the conservation in the CDR3 is that it reflects selective recruitment of TCRs with an optimal fit for the peptide. 23 It is difficult to envision how this could occur if recognition were poly-specific or peptidedegenerate. It seems reasonable to assume that if one alloreactive receptor can recognize multiple structurally unrelated peptides, a given peptide should be recognized by structurally distinct receptors. The large set of MHCp complexes that are presented in the thymus might effectively deplete T cells with high affinity for structures shared by MHC molecules. Our results could argue for a modified view of allo-reactivity: the mature TCR repertoire is depleted for self-reactivity, but recognition of any other MHCp complex is independent of the MHC background of the T cells. Thus, although poly-specificity is certainly a feature of some allo-reactive TCRs, 8, 29 there is now also convincing evidence for the poly-specificity of peptides presented on self-MHC. [30] [31] [32] Consequently, it may not be necessary to apply a specific set of rules for allo-recognition to explain why so many receptors are engaged in allo-reactions. Although our results clearly show that allo-reactive cells are not inherently poly-specific, it is important to bear in mind that we studied a single HLA-peptide complex. It is possible that specificity is critically dependent on the peptide that is presented by the allogeneic HLA molecule. Nevertheless, the exquisite specificity that was obtained for the CD20-specific TCRs is encouraging and provides a rationale to pursue this and other allo-antigens as therapeutic targets. An important question is how allo-restricted CTLs can be used to improve the treatment of B cell malignancies. Stem cell transplantation is currently the only curative option for CLL. 33 However, the treatment-related mortality is as high as 30-44%. 33 As the T cells generated here were specific for HLA-A2/CD20 when tested on a wide range of HLA-mismatched cells, the most important limitation is likely to be host rejection rather than graft-versus-host activity. One possibility is to use expanded CTLs in patients positive for HLA-A*0201, which is present in approximately 50% of the Caucasian population. It is feasible to identify donors that are HLA-A2 neg but otherwise HLA-identical with the patient, being homozygous for the second HLA-A allele of the recipient. The patient would receive chemotherapy to reduce tumor cell load and prevent rejection of the infused HLA-A2/CD20-specific allogeneic T cells. As the single HLA antigen mismatch would be in the desired donor-torecipient direction only, the risk of rejection is reduced to minor histocompatibility antigens. 34 This risk is probably relatively small, as even adoptively transferred allogeneic EBV-specific T cells that are mismatched on multiple HLA antigens are not rejected (or cause graft-versus-host disease), and efficiently cure EBV-positive post-transplantation lymphoproliferative disease. 35 The HLA-A2/CD20-specific CTLs could be administered together with a T cell-depleted stem cell graft from the same (HLA-A2 neg ) donor. The CD20-specific CTLs would be patient-specific, permitting B lymphopoiesis from the transplanted stem cells. However, the experience with treatment of lymphoma using monoclonal antibodies to CD20 (Rituximab) shows that B cell depletion does not represent a major safety issue. 36 Alternatively, the cloned TCRs can be expressed in the patient T cells ex vivo and subsequently re-infused. 37 Rosenberg et al. have successfully used such a strategy to induce T cell responses to melanoma. 38 As HLA-A2 is widely expressed in the population, it might be possible to use the same TCRs to treat a large number of patients. Polyclonal T cells derived from the patient, or donor-derived T cells with a defined specificity (for example, for EBV), could be expanded in vitro and 're-directed' 39, 40 with CD20-specific TCRs. Therapy with Rituximab results in clinical responses in approximately 50% of patients with B cell non-Hodgkin's lymphomas, but all patients treated eventually relapse, 41 and it is inefficient as monotherapy of CLL despite expression of CD20. 42 It is notable that T cells and antibodies provide cytotoxicity by different mechanisms. [41] [42] [43] T cell-mediated killing by perforin/granzyme is independent of p53, whereas resistance to chemotherapy is frequently related to loss of p53 function.
43 CD20-specific T cells could therefore provide better or synergistic effects in combination with standard therapeutic modalities.
In conclusion, the results presented here bear promise that allo-restricted T cells may efficiently induce graft-versusleukemia without graft-versus-host disease, and that a high degree of target specificity can be obtained with allo-restricted TCRs. Given that CD20 is found on the majority of B cell malignancies, immunotherapy using T cells with endogenous or induced expression of allo-restricted, CD20-specific TCRs might have a wide applicability.
